<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4181">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757285</url>
  </required_header>
  <id_info>
    <org_study_id>0304842</org_study_id>
    <nct_id>NCT04757285</nct_id>
  </id_info>
  <brief_title>Copeptin and Psychological Stress of Medic During COVID-19 Pandemic</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Evaluation of Serum Copeptin and Psychological Stress Level Among Healthcare Providers During COVID-19 Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psychological stress (PSS) is one of the most common problems among healthcare providers&#xD;
      during COVID-19 pandemic. PSS influences the homeostatic equilibrium of the body, involving&#xD;
      activation of the sympathetic nervous system and hypothalamus pituitary adrenal (HPA) axis.&#xD;
      Copeptin; C-terminal portion of Vasopressin (AVP) precursor is stable. Nevertheless, Evidence&#xD;
      about influence of PSS on copeptin levels is lacking. The reason we are doing this research&#xD;
      is to determine the level of psychological stress among healthcare providers exposed to at&#xD;
      the time of work in intensive care unit (ICU) during COVID-19 pandemic; They will be&#xD;
      appraised every assembly for psychological stress level; before start of duty shifts (first&#xD;
      time), one week after start (second time) and two weeks after departure from shift duties in&#xD;
      ICU (third time) for assessment of psychological stress level and stress hormones.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 70 healthcare personnel volunteers participated; 35 physicians and 35 nurses. All&#xD;
      healthcare providers' volunteers are in good physical health, Exclusion criteria included&#xD;
      hypertension, diabetes mellitus, obesity BMI ≥30, subjects with serum sodium ≤135 or ≥ 145&#xD;
      mmol /L at baseline or females receiving contraceptive pills.&#xD;
&#xD;
      During the research participants will answer a questionnaire as well as three blood samples&#xD;
      are taken.&#xD;
&#xD;
        -  In the first meeting, evaluation of participant general condition; determining BMI,&#xD;
           blood pressure. Then a small amount of blood, equal to about two millimeters, will be&#xD;
           taken from participant arm with a syringe. This blood will be tested for serum copeptin,&#xD;
           cortisol (fasting morning sample). The investigator will ask participant few questions&#xD;
           to evaluate the level of stress (as anxiety, insomnia, fear of infection through&#xD;
           questionnaire)&#xD;
&#xD;
        -  The second meeting, one week after work in ICU, another blood sample will be taken from&#xD;
           participant and determine level of psychological stress.&#xD;
&#xD;
        -  The third meeting, two weeks after leave from ICU participant blood sample will be taken&#xD;
           from participant to determine stress hormones and determine level of psychological&#xD;
           stress.&#xD;
&#xD;
      Duration&#xD;
&#xD;
      The research takes place over six months in total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2020</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>evaluation of psychological stress</measure>
    <time_frame>four weeks for each participant.</time_frame>
    <description>- Primarily outcome determination of psychological stress among doctors and nurses working in ICU through a questionnaire before duty shifts [first time] and re-evaluate it after one week of work in ICU [second time], and lastly two weeks after departure from shift duties [third time].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>determine stress hormones in serum cortisol and copeptin</measure>
    <time_frame>four weeks for each participant..</time_frame>
    <description>Second to determine stress hormones copeptin and cortisol (possible stress biomarkers) concurrently with questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation of psychological stress with stress hormone copeptin</measure>
    <time_frame>four weeks for each participant..</time_frame>
    <description>correlate the level of psychological stress calculated from provided questionnaire in the three assemblies with stress biomarkers copeptin and cortisol in the three measurements.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Psychological Stress</condition>
  <condition>Hemostatic Disorder</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>25 healthcare personnel volunteers not working in quarantine hospitals of matched age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthcare providers worked in Intensive Care Units</arm_group_label>
    <description>35 physicians (28 males and 7 females) and 35 nurses (10 males and 25 females). All volunteers were in good physical health Exclusion criteria included hypertension, diabetes mellitus, obesity BMI ≥30, subjects with serum sodium ≤135 or ≥ 145 mmol /L at baseline or females receiving contraceptive pills.&#xD;
Assigned participants were clinically evaluated for as hypertension, DM, dyslipidemia, renal function.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Healthcare providers worked in ICU: 35 physicians (28 males and 7 females) and 35 nurses&#xD;
        (10 males and 25 females). Age ranged from 24 to 37 years All volunteers were in good&#xD;
        physical health Exclusion criteria included hypertension, diabetes mellitus, obesity BMI&#xD;
        ≥30, subjects with serum sodium ≤135 or ≥ 145 mmol /L at baseline or females receiving&#xD;
        contraceptive pills.&#xD;
&#xD;
        Group Information healthcare providers designated to take duty shifts at ICU in Alexandria&#xD;
        quarantine hospitals for two weeks during COVID-19 pandemic. And a control group of&#xD;
        healthcare providers not assigned to work in quarantine hospitals.&#xD;
&#xD;
        First assembly one day before enrolling to work in ICU. Second assembly at the end of first&#xD;
        week of work, third assembly two weeks after departure from work in ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        physicians and nurses under age of 37 years in good health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  body mass index above 30&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  females receiving contraceptive pills&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexandria University Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8(4):367-81. Review.</citation>
    <PMID>17290796</PMID>
  </results_reference>
  <results_reference>
    <citation>Christ-Crain M, Fenske W. Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol. 2016 Mar;12(3):168-76. doi: 10.1038/nrendo.2015.224. Epub 2016 Jan 22. Review.</citation>
    <PMID>26794439</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>hala mourad demerdash</investigator_full_name>
    <investigator_title>Consultant Clinical Pathology</investigator_title>
  </responsible_party>
  <keyword>psychological stress</keyword>
  <keyword>copeptin</keyword>
  <keyword>hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

